Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | BCAT1 | P54687 | 6/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.38 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3102517 | 0.86 | TTR (0.47) | TTRBCAT1KMT2AVNN1IDO1 | |
| SCHEMBL3103247 | 0.80 | SIGMAR1 (0.39) | MCHR1LMNA | |
| SCHEMBL3104475 | 0.78 | KDM4E (0.45) | RAB9AMEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL2019989 | 0.77 | KDM4E (0.56) | — | |
| SCHEMBL21162194 | 0.75 | ELOVL6 (0.53) | VNN1ELOVL6 | |
| SCHEMBL21634016 | 0.72 | VNN1 (0.39) | NPC1RAB9AKMT2AVNN1PRMT5 | |
| SCHEMBL9535481 | 0.72 | TTR (0.57) | TTRNPC1RAB9ABCAT1LMNA | |
| SCHEMBL13431290 | 0.71 | SRD5A2 (0.47) | LMNAHTTVNN1PRMT5WDR77 | |
| SCHEMBL3225516 | 0.71 | SRD5A2 (0.47) | LMNAHTTVNN1PRMT5WDR77 | |
| SCHEMBL3106941 | 0.71 | SRD5A2 (0.47) | LMNAHTTVNN1PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056600-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC | 2010-03-04 | — | — | US | claimed |
| EP-2141990-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2010-01-13 | — | — | EP | claimed |
| WO-2008119017-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-10-02 | — | — | WO | claimed |
| US-20100056600-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC | 2010-03-04 | — | — | US | disclosed |
| US-20100056600-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC | 2010-03-04 | — | — | US | disclosed |
| US-20100056600-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC | 2010-03-04 | — | — | US | disclosed |
| EP-2141990-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119017-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008119017-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056600-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HSD11B1, HSD3B1, HSD11B2 | TTR 2383/4885NPC1 283/4885RAB9A 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.